According to a recent LinkedIn post from KROMATID, the company is highlighting the contribution of its VP of Platform, Erin Cross, to the newly released third edition of the reference volume “Fluorescence In Situ Hybridization (FISH): Application Guide.” The book compiles updated protocols across FISH and comparative genomic hybridization, including multicolor FISH, cryptic aberration detection, nuclear architecture, epigenetics, single-cell methods, sequencing, and CRISPR/Cas9 applications.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that KROMATID views scientific authorship and community knowledge sharing as integral to its strategy in genomic structural analysis. For investors, visible leadership in technical standards and methods may enhance the company’s credibility with researchers and biopharma partners, potentially supporting adoption of its platforms in cell and gene therapy workflows over time.
The emphasis on safer and more reliable cell and gene therapies aligns KROMATID with a growing segment of the life sciences market focused on high-precision genomic tools. While the LinkedIn content does not reference specific commercial products, revenue, or partnerships, it indicates ongoing investment in expertise and reputation-building, which could strengthen the company’s competitive position in advanced genomic analytics.